Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia

Inclusion Criteria: * Male or female, aged 18-65 years with AGA * Completed and signed consent form * Norwood Hamilton stage II-V in men or Ludwig stage I2-II1 in women * In general good health * Willing and able to attend all study visits * Willing to maintain the same hair style and hair care routine as at the screening visit for the duration of the study * Willing to have blood drawn Exclusion Criteria: * Younger than 18 years or older than 65 years * Diagnosis of alopecia areata or other non-AGA forms of hair loss * Current skin disease, cuts, or abrasions on the scalp (i.e. psoriasis, severe seborrheic dermatitis) that may limit data interpretation or put the subject at increased risk * Scalp infection * Malignancy, except for non-scalp nonmelanoma or melanoma skin cancers, or undergoing chemotherapy or radiation treatments * Known history of autoimmune thyroid disease, any other thyroid disorder, or other autoimmune disorders that may interfere or increase risks associated with the study treatment * Pregnancy, anticipated pregnancy, or breastfeeding * Tendency to develop keloids * History of surgical correction of hair loss on the scalp * Use of products, devices, or medications intended to promote hair growth, except for subjects whose hair has been stable on FDA-approved therapies (i.e. oral finasteride and/or topical minoxidil) for 12 months * Use of anti-androgenic therapies (i.e. spironolactone, flutamide, cyproterone, acetate, cimetidine) within 90 days prior to he screening visit * Current anticoagulant therapy, except for subjects taking aspirin or other nonsteroidal anti-inflammatory drugs who are able to interrupt the medication for seven days before treatment or for subjects taking vitamin E or other over-the-counter supplements who are able to interrupt the medication for 14 days before treatment * Hereditary or acquired hematologic/coagulation disorders including: platelet dysfunction syndrome or thrombocytopenia (count \< 150,000 platelets/Ul), hypofibrinogenemia, impaired coagulation, drepanocytosis (sickle cell anemia) * Hemodynamic instability